These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 26550540)
41. Design, Synthesis, and Biological Evaluation of Liu F; Liu T; Xu X; Guo X; Li N; Xiong C; Li C; Zhu H; Yang Z Mol Pharm; 2018 Feb; 15(2):619-628. PubMed ID: 29278911 [TBL] [Abstract][Full Text] [Related]
42. Antiphosphatidylserine antibody combined with irradiation damages tumor blood vessels and induces tumor immunity in a rat model of glioblastoma. He J; Yin Y; Luster TA; Watkins L; Thorpe PE Clin Cancer Res; 2009 Nov; 15(22):6871-80. PubMed ID: 19887482 [TBL] [Abstract][Full Text] [Related]
43. Synthesis and evaluation of novel gonadotropin-releasing hormone receptor-targeting peptides. Guo H; Lu J; Hathaway H; Royce ME; Prossnitz ER; Miao Y Bioconjug Chem; 2011 Aug; 22(8):1682-9. PubMed ID: 21749045 [TBL] [Abstract][Full Text] [Related]
44. PET Imaging of HER2-Positive Tumors with Cu-64-Labeled Affibody Molecules. Qi S; Hoppmann S; Xu Y; Cheng Z Mol Imaging Biol; 2019 Oct; 21(5):907-916. PubMed ID: 30617730 [TBL] [Abstract][Full Text] [Related]
45. Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5. Tsai SW; Sun Y; Williams LE; Raubitschek AA; Wu AM; Shively JE Bioconjug Chem; 2000; 11(3):327-34. PubMed ID: 10821648 [TBL] [Abstract][Full Text] [Related]
46. Affinity maturation of an ERBB2-targeted SPECT imaging peptide by in vivo phage display. Larimer BM; Thomas WD; Smith GP; Deutscher SL Mol Imaging Biol; 2014 Aug; 16(4):449-58. PubMed ID: 24550054 [TBL] [Abstract][Full Text] [Related]
47. Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with 64Cu-labeled bevacizumab in colorectal cancer xenografts. Paudyal B; Paudyal P; Oriuchi N; Hanaoka H; Tominaga H; Endo K Cancer Sci; 2011 Jan; 102(1):117-21. PubMed ID: 21070475 [TBL] [Abstract][Full Text] [Related]
48. Preclinical evaluation of [¹¹¹ In]-DOTA-trastuzumab for clinical trials. Alirezapour B; Jalilian AR; Rajabifar S; Mirzaii M; Moradkhani S; Pouladi M; Aslani G J Cancer Res Ther; 2014; 10(1):112-20. PubMed ID: 24762497 [TBL] [Abstract][Full Text] [Related]
49. DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use. Klingler M; Summer D; Rangger C; Haubner R; Foster J; Sosabowski J; Decristoforo C; Virgolini I; von Guggenberg E J Nucl Med; 2019 Jul; 60(7):1010-1016. PubMed ID: 30530828 [TBL] [Abstract][Full Text] [Related]
51. Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules. Perols A; Honarvar H; Strand J; Selvaraju R; Orlova A; Karlström AE; Tolmachev V Bioconjug Chem; 2012 Aug; 23(8):1661-70. PubMed ID: 22768790 [TBL] [Abstract][Full Text] [Related]
52. 68Ga-DOTA-NGR as a novel molecular probe for APN-positive tumor imaging using MicroPET. Zhang J; Lu X; Wan N; Hua Z; Wang Z; Huang H; Yang M; Wang F Nucl Med Biol; 2014 Mar; 41(3):268-75. PubMed ID: 24438818 [TBL] [Abstract][Full Text] [Related]
53. Synthesis and evaluation of Yang Y; Zhang J; Zou H; Shen Y; Deng S; Wu Y J Cancer; 2021; 12(1):244-252. PubMed ID: 33391421 [No Abstract] [Full Text] [Related]
55. A Novel Small Cyclic Peptide-Based Liu H; Hu M; Deng J; Zhao Y; Peng D; Feng Y; Wang L; Chen Y; Qiu L Mol Pharm; 2022 Jan; 19(1):138-147. PubMed ID: 34910492 [TBL] [Abstract][Full Text] [Related]